Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 5/2014

01-10-2014 | Original Paper

BMP9 regulates cross-talk between breast cancer cells and bone marrow-derived mesenchymal stem cells

Authors: Shaoheng Wan, Yuehong Liu, Yaguang Weng, Wei Wang, Wei Ren, Chang Fei, Yingying Chen, Zhihui Zhang, Ting Wang, Jinshu Wang, Yayun Jiang, Lan Zhou, Tongchuan He, Yan Zhang

Published in: Cellular Oncology | Issue 5/2014

Login to get access

Abstract

Purpose

Breast cancer cells frequently metastasize to distant organs, including bone. Interactions between breast cancer cells and the bone microenvironment are known to enhance tumor growth and osteolytic damage. Here we investigated whether BMP9 (a secretary protein) may change the bone microenvironment and, by doing so, regulate the cross-talk between breast cancer cells and bone marrow-derived mesenchymal stem cells.

Methods

After establishing a co-culture system composed of MDA-MB-231breast cancer cells and HS-5 bone marrow-derived mesenchymal stem cells, and exposure of this system to BMP9 conditioned media, we assessed putative changes in migration and invasion capacities of MDA-MB-231 cells and concomitant changes in osteogenic marker expressionin HS-5 cells and metastases-related genes in MDA-MB-231 cells.

Results

We found that BMP9 can inhibit the migration and invasion of MDA-MB-231 cells, and promote osteogenesis and proliferation of HS-5 cells, in the co-culture system. We also found that the BMP9-induced inhibition of migration and invasion of MDA-MB-231 cells may be caused by a decreased RANK ligand (RANKL) secretion by HS-5 cells, leading to a block in the AKT signaling pathway.

Conclusions

From our data we conclude that BMP9 inhibits the migration and invasion of breast cancer cells, and promotes the osteoblastic differentiation and proliferation of bone marrow-derived mesenchymal stem cells by regulating cross-talk between these two types of cells through the RANK/RANKL signaling axis.
Literature
1.
A. Halon, P. Donizy, P. Surowiak, R. Matkowski, ERM/Rho protein expression in ductal breast cancer: a 15 year follow-up. Cell Oncol (Dordr) 36, 181–190 (2013)CrossRef
2.
A. Lipton, R. Uzzo, R.J. Amato, G.K. Ellis, B. Hakimian, G.D. Roodman, M.R. Smith, The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. J Natl Compr Cancer Netw 7(Suppl 7), S1–S29 (2009). quiz S30
3.
I. Zinonos, K.W. Luo, A. Labrinidis, V. Liapis, S. Hay, V. Panagopoulos, M. Denichilo, C.H. Ko, G.G. Yue, C.B. Lau, W. Ingman, V. Ponomarev, G.J. Atkins, D.M. Findlay, A.C. Zannettino, A. Evdokiou, Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer. Int. J. Oncol. 45, 532–540 (2014)PubMedPubMedCentral
4.
R.L. Theriault, R.L. Theriault, Biology of bone metastases. Cancer Control 19, 92–101 (2012)PubMed
5.
R. Krawetz, Y.E. Wu, D.E. Rancourt, J. Matyas, Osteoblasts suppress high bone turnover caused by osteolytic breast cancer in-vitro. Exp. Cell Res. 315, 2333–2342 (2009)PubMedCrossRef
6.
P.O. Favaron, A. Mess, S.E. Will, P.C. Maiorka, M.F. de Oliveira, M.A. Miglino, Yolk sac mesenchymal progenitor cells from New World mice (Necromys lasiurus) with multipotent differential potential. PLoS One 9, e95575 (2014)PubMedCrossRefPubMedCentral
7.
J. Luo, M. Tang, J. Huang, B.C. He, J.L. Gao, L. Chen, G.W. Zuo, W. Zhang, Q. Luo, Q. Shi, B.Q. Zhang, Y. Bi, X. Luo, W. Jiang, Y. Su, J. Shen, S.H. Kim, E. Huang, Y. Gao, J.Z. Zhou, K. Yang, H.H. Luu, X. Pan, R.C. Haydon, Z.L. Deng, T.C. He, TGFbeta/BMP type I receptors ALK1 and ALK2 are essential for BMP9-induced osteogenic signaling in mesenchymal stem cells. J. Biol. Chem. 285, 29588–29598 (2010)PubMedCrossRefPubMedCentral
8.
D. Mendoza-Villanueva, L. Zeef, P. Shore, Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFβ-dependent expression of the Wnt antagonist, sclerostin. Breast Cancer Res. 13, R106 (2011)PubMedCrossRefPubMedCentral
9.
A.P. Molloy, F.T. Martin, R.M. Dwyer, T.P. Griffin, M. Murphy, F.P. Barry, T. O’Brien, M.J. Kerin, Mesenchymal stem cell secretion of chemokines during differentiation into osteoblasts, and their potential role in mediating interactions with breast cancer cells. Int. J. Cancer 124, 326–332 (2009)PubMedCrossRef
10.
K. Wang, H. Feng, W. Ren, X. Sun, J. Luo, M. Tang, L. Zhou, Y. Weng, T.C. He, Y. Zhang, BMP9 inhibits the proliferation and invasiveness of breast cancer cells MDA-MB-231. J. Cancer Res. Clin. Oncol. 137, 1687–1696 (2011)PubMedCrossRef
11.
X. Sun, K. Wang, H. Feng, Effects and possible mechanism of BMP9 on the bone metastasis of human breast cancer cells MDA-MB- 231. Chin Biotechnol 32, 7–13 (2012)
12.
N. Tang, W.X. Song, J. Luo, X. Luo, J. Chen, K.A. Sharff, Y. Bi, B.C. He, J.Y. Huang, G.H. Zhu, Y.X. Su, W. Jiang, M. Tang, Y. He, Y. Wang, L. Chen, G.W. Zuo, J. Shen, X. Pan, R.R. Reid, H.H. Luu, R.C. Haydon, T.C. He, BMP-9-induced osteogenic differentiation of mesenchymal progenitors requires functional canonical Wnt/beta-catenin signalling. J. Cell. Mol. Med. 13, 2448–2464 (2009)PubMedCrossRef
13.
N. Serna-Marquez, S. Villegas-Comonfort, O. Galindo-Hernandez, N. Navarro-Tito, A. Millan, E.P. Salazar, Role of LOXs and COX-2 on FAK activation and cell migration induced by linoleic acid in MDA-MB-231 breast cancer cells. Cell Oncol 36, 65–77 (2013)CrossRef
14.
J.S. Park, S.Y. Choi, J.H. Lee, J.H. Lee, M. Lee, E.S. Nam, A.L. Jeong, S. Lee, S. Han, M.S. Lee, J.S. Lim, Y. Yoon do, Y. Kwon, Y. Yang, Interleukin-32β stimulates migration of MDA-MB-231 and MCF-7cells via the VEGF-STAT3 signaling pathway. Cell Oncol 36, 493–503 (2013)CrossRef
15.
H.H. Luu, W.X. Song, X. Luo, D. Manning, J. Luo, Z.L. Deng, K.A. Sharff, A.G. Montag, R.C. Haydon, T.C. He, Distinct roles of bone morphogenetic proteins in osteogenic differentiation of mesenchymal stem cells. J. Orthop. Res. 25, 665–677 (2007)PubMedCrossRef
16.
17.
J.L. Gilmore, J.A. Scott, Z. Bouizar, A. Robling, S.E. Pitfield, D.J. Riese 2nd, J. Foley, Amphiregulin-EGFR signaling regulates PTHrP gene expression in breast cancer cells. Breast Cancer Res. Treat. 110, 493–505 (2008)PubMedCrossRefPubMedCentral
18.
S. Ley, A. Weigert, B. Weichand, N. Henke, B. Mille-Baker, R.A. Janssen, B. Brune, The role of TRKA signaling in IL-10 production by apoptotic tumor cell-activated macrophages. Oncogene 32, 631–640 (2013)PubMedCrossRef
19.
J.Y. Jang, Y.K. Jeon, C.W. Kim, Degradation of HER2/neu by ANT2 shRNA suppresses migration and invasiveness of breast cancer cells. BMC Cancer 10, 391 (2010)PubMedCrossRefPubMedCentral
20.
K. Tawara, J.T. Oxford, C.L. Jorcyk, Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies. Cancer Manag. Res. 3, 177–189 (2011)PubMedPubMedCentral
21.
Y. Guo, P.F. Li, X.C. Shu, H. Deng, H.L. Ma, L. Sun, Involvement of Wnt/beta-catenin signaling in the osteogenesis of bone marrow mesenchymal stem cells induced by drynaria total flavonoids. Zhonghua Yi Xue Za Zhi 92, 2288–2291 (2012)PubMed
22.
L. Zhang, Y. Teng, Y. Zhang, J. Liu, L. Xu, J. Qu, K. Hou, X. Yang, Y. Liu, X. Qu, C-Src-mediated RANKL-induced breast cancer cell migration by activation of the ERK and Akt pathway. Oncol Lett 3, 395–400 (2012)PubMedPubMedCentral
23.
Y. Zhang, L. Wang, M. Zhang, M. Jin, C. Bai, X. Wang, Potential mechanism of interleukin-8 production from lung cancer cells: an involvement of EGF-EGFR-PI3K-Akt-Erk pathway. J. Cell. Physiol. 227, 35–43 (2012)PubMedCrossRef
24.
S. Ibaragi, T. Shimo, M. Iwamoto, N.M. Hassan, S. Kodama, S. Isowa, A. Sasaki, Parathyroid hormone-related peptide regulates matrix metalloproteinase-13 gene expression in bone metastatic breast cancer cells. Anticancer Res. 30, 5029–5036 (2010)PubMed
25.
L. Zhang, Y. Teng, Y. Zhang, J. Liu, L. Xu, J. Qu, K. Hou, Y. Liu, X. Qu, Proteasome inhibitor bortezomib (PS-341) enhances RANKL-induced MDA-MB-231 breast cancer cell migration. Mol Med Rep 5, 580–584 (2012)PubMed
26.
L. Ye, H. Kynaston, W.G. Jiang, Bone morphogenetic protein-9 induces apoptosis in prostate cancer cells, the role of prostate apoptosis response-4. Mol. Cancer Res. 6, 1594–1606 (2008)PubMedCrossRef
27.
L. Ye, H. Kynaston, W.G. Jiang, Bone morphogenetic protein-10 suppresses the growth and aggressiveness of prostate cancer cells through a Smad independent pathway. J. Urol. 181, 2749–2759 (2009)PubMedCrossRef
28.
29.
30.
W. Ren, X. Sun, K. Wang, H. Feng, Y. Liu, C. Fei, S. Wan, W. Wang, J. Luo, Q. Shi, M. Tang, G. Zuo, Y. Weng, T. He, Y. Zhang, BMP9 inhibits the bone metastasis of breast cancer cells by downregulating CCN2 (connective tissue growth factor, CTGF) expression. Mol. Biol. Rep. 41, 1373–1383 (2014)PubMedCrossRef
31.
Y.H. Wang, Y.Y. Dong, W.M. Wang, X.Y. Xie, Z.M. Wang, R.X. Chen, J. Chen, D.M. Gao, J.F. Cui, Z.G. Ren, Vascular endothelial cells facilitated HCC invasion and metastasis through the Akt and NF-κB pathways induced by paracrine cytokines. J. Exp. Clin. Cancer Res. 32, 51 (2013)PubMedCrossRefPubMedCentral
32.
A. De Luca, L. Lamura, M. Gallo, V. Maffia, N. Normanno, Mesenchymal stem cell-derived interleukin-6 and vascular endothelial growth factor promote breast cancer cell migration. J. Cell. Biochem. 113, 3363–3370 (2012)PubMedCrossRef
33.
L.E. Wright, J.B. Frye, A.L. Lukefahr, B.N. Timmermann, K.S. Mohammad, T.A. Guise, J.L. Funk, Curcuminoids block TGF-β signaling in human breast cancer cells and limit osteolysis in a murine model of breast cancer bone metastasis. J. Nat. Prod. 76, 316–321 (2013)PubMedCrossRefPubMedCentral
34.
S. Das, R.S. Samant, L.A. Shevde, Hedgehog signaling induced by breast cancer cells promotes osteoclastogenesis and osteolysis. J. Biol. Chem. 286, 9612–9622 (2011)PubMedCrossRefPubMedCentral
35.
S. Das, J.A. Tucker, S. Khullar, R.S. Samant, L.A. Shevde, Hedgehog signaling in tumor cells facilitates osteoblast-enhanced osteolytic metastases. PLoS One 7, e34374 (2012)PubMedCrossRefPubMedCentral
36.
T.A. Owen, M. Aronow, V. Shalhoub, L.M. Barone, L. Wilming, M.S. Tassinari, M.B. Kennedy, S. Pockwinse, J.B. Lian, G.S. Stein, Progressive development of the rat osteoblast phenotype in vitro: reciprocal relationships in expression of genes associated with osteoblast proliferation and differentiation during formation of the bone extracellular matrix. J. Cell. Physiol. 143, 420–430 (1990)PubMedCrossRef
37.
G. Bu, W. Lu, C.C. Liu, K. Selander, T. Yoneda, C. Hall, E.T. Keller, Y. Li, Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases. Int. J. Cancer 123, 1034–1042 (2008)PubMedCrossRefPubMedCentral
38.
Z. Zhai, X. Qu, W. Yan, H. Li, G. Liu, X. Liu, T. Tang, A. Qin, K. Dai, Andrographolide prevents human breast cancer-induced osteoclastic bone loss via attenuated RANKL signaling. Breast Cancer Res. Treat. 144, 33–45 (2014)PubMedCrossRef
39.
N. Kurio, T. Shimo, T. Fukazawa, M. Takaoka, T. Okui, N.M. Hassan, T. Honami, S. Hatakeyama, M. Ikeda, Y. Naomoto, A. Sasaki, Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo. Exp. Cell Res. 317, 1134–1146 (2011)PubMedCrossRef
40.
C. Bolin, K. Tawara, C. Sutherland, J. Redshaw, P. Aranda, J. Moselhy, R. Anderson, C.L. Jorcyk, Oncostatin m promotes mammary tumor metastasis to bone and osteolytic bone degradation. Genes Cancer 3, 117–130 (2012)PubMedCrossRefPubMedCentral
Metadata
Title
BMP9 regulates cross-talk between breast cancer cells and bone marrow-derived mesenchymal stem cells
Authors
Shaoheng Wan
Yuehong Liu
Yaguang Weng
Wei Wang
Wei Ren
Chang Fei
Yingying Chen
Zhihui Zhang
Ting Wang
Jinshu Wang
Yayun Jiang
Lan Zhou
Tongchuan He
Yan Zhang
Publication date
01-10-2014
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 5/2014
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-014-0197-1

Other articles of this Issue 5/2014

Cellular Oncology 5/2014 Go to the issue

Original Paper

Robust meta-analysis shows that glioma transcriptional subtyping complements traditional approaches

Original Paper

Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology

Original Paper

A novel saliva-based microRNA biomarker panel to detect head and neck cancers

Original Paper

Apoptosis induction and anti-cancer activity of LeciPlex formulations

Original Paper

Gefitinib induces cytoplasmic translocation of the CDK inhibitor p27 and its binding to a cleaved intermediate of caspase 8 in non-small cell lung cancer cells

Review

Nestin involvement in tissue injury and cancer - a potential tumor marker?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits